CERENO SCIENTIFIC AB B Cash Flow Conversion Efficiency
CERENO SCIENTIFIC AB B cash flow conversion efficiency. Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) has a cash flow conversion efficiency ratio of 0.105x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€20.90 Million ≈ $24.43 Million USD) by net assets (€198.40 Million ≈ $231.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CERENO SCIENTIFIC AB B (2021–2025)
Cash flow conversion efficiency of CERENO SCIENTIFIC AB B from 2021 to 2025. This chart illustrates how CERENO SCIENTIFIC AB B's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CERENO SCIENTIFIC AB B (4A1) stock price for real-time trading data and today's change.
CERENO SCIENTIFIC AB B Cash Flow Conversion Ratio Explained
CERENO SCIENTIFIC AB B cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CERENO SCIENTIFIC AB B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CERENO SCIENTIFIC AB B ranked by their cash flow conversion efficiency. Also see market cap of CERENO SCIENTIFIC AB B for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Queenco-L
TA:QNCO
|
0.032x |
|
NeueHealth Inc
NYSE:NEUE
|
0.007x |
|
Semyung Electric Machinery Co.Ltd
KQ:017510
|
0.207x |
|
Gold Pacific Co. Ltd
KQ:038530
|
0.000x |
|
Thermaltake Technology Co Ltd
TWO:3540
|
-0.081x |
|
Arn Media Ltd
AU:A1N
|
0.128x |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
0.070x |
|
Guillemot Corporation S.A.
PA:GUI
|
-0.006x |
Annual Cash Flow Conversion Efficiency for CERENO SCIENTIFIC AB B (2021–2025)
The table below shows the annual cash flow conversion efficiency of CERENO SCIENTIFIC AB B from 2021 to 2025. Review 4A1 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €252.60 Million ≈ $295.31 Million |
€-111.93 Million ≈ $-130.86 Million |
-0.443x | +17.76% |
| 2024-12-31 | €191.93 Million ≈ $224.38 Million |
€-103.42 Million ≈ $-120.91 Million |
-0.539x | -215.92% |
| 2023-12-31 | €216.42 Million ≈ $253.02 Million |
€-36.92 Million ≈ $-43.16 Million |
-0.171x | -84.64% |
| 2022-12-31 | €201.51 Million ≈ $235.59 Million |
€-18.62 Million ≈ $-21.76 Million |
-0.092x | -19.59% |
| 2021-12-31 | €170.06 Million ≈ $198.82 Million |
€-13.14 Million ≈ $-15.36 Million |
-0.077x | -- |
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as a… Read more